


Claims

1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers thereof.

2. A compound according to claim 1, as the free base.
3. A compound according to claim 2, as the anhydrous free base in solid crystalline form.
4. A compound according to claim 3, wherein the compound of formula (I) as the anhydrous free base is in solid crystalline form having the X-ray powder diffraction pattern substantially as shown in Figure 1 (Form A).
5. A compound according to claim 3, wherein the compound of formula (I) as the anhydrous free base is in solid crystalline form having an X-ray powder diffraction pattern containing one, two, three, four, five, six or seven peaks selected from ($\pm$ 0.2) 10.3, 15.2, 17.5, 23.1, 24.6, 26.7 and 27.4 degrees 2-theta.
6. A compound according to claim 3, wherein the compound of formula (I) as the anhydrous free base is in solid crystalline form having the X-ray powder diffraction pattern substantially as shown in Figure 2 (Form B).
7. A compound according to claim 3, wherein the compound of formula (I) as the anhydrous free base is in solid crystalline form having an X-ray powder diffraction pattern containing one, two, three, four, five, six, seven or all eight peaks selected from ($\pm$ 0.2) 3.9, 6.1, 11.8, 14.3, 16.7, 18.3, 18.7 and 28.9 degrees 2-theta.
8. A pharmaceutical composition comprising a compound according to any of claims 1 to 7, in combination with one or more pharmaceutically acceptable diluents or carriers.
9. A compound of formula (I) according to any of claims 1 to 7 for use as a medicament.

10. A compound of formula (I) according to any of claims 1 to 7 or a pharmaceutical composition according to claim 8 for use in the treatment or prevention of exacerbations in patients with chronic respiratory disease, such as COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis.
11. A compound of formula (I) according to any of claims 1 to 7 or a pharmaceutical composition according to claim 8 for use in the treatment or prevention of a condition selected from: COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.
12. Use of a compound of formula (I) according to any of claims 1 to 7 or a pharmaceutical composition according to claim 8 for the manufacture of a medicament for the treatment or prevention of a condition selected from: COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, pulmonary hypertension, allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.
13. A method of treatment of a condition selected from COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma which comprises administering to a subject an effective amount of a compound of formula (I) according to any of claims 1 to 7 or a pharmaceutical composition according to claim 8.
14. A compound of formula (I) according to any of claims 1 to 7 or a pharmaceutical composition according to claim 8 for use as in the treatment or prevention of respiratory viral infections in patients with chronic conditions such as congestive heart failure, diabetes, cancer, or in immunosuppressed patients, for example post-


organ transplant.

15. A compound of formula (I) according to any of claims 1 to 7 or a pharmaceutical composition according to claim 8 in combination with anti-viral therapy such as zanamivir or oseltamivir (for example oseltamivir phosphate), for use in the treatment or prevention of respiratory viral infections in patients with chronic conditions such as congestive heart failure, diabetes, cancer, or in immunosuppressed patients, for example post-organ transplant.
16. A combination product comprising:
- (A) a compound of formula (I) according to any of claims 1 to 7; and
 - (B) another therapeutic agent;
- 5 wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable diluent or carrier;
- wherein said combination product may be either a single pharmaceutical formulation or a kit-of-parts.

10

Claims

1. A compound of formula (I)



- or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers thereof.
2. A compound according to claim 1, as the free base.
3. A compound according to claim 2, as the anhydrous free base in solid crystalline form.
4. A compound according to claim 3, wherein the compound of formula (I) as the anhydrous free base is in solid crystalline form having an X-ray powder diffraction pattern containing seven peaks selected from (± 0.2) 10.3, 15.2, 17.5, 23.1, 24.6, 26.7 and 27.4 degrees 2-theta.
5. A compound according to claim 3, wherein the compound of formula (I) as the anhydrous free base is in solid crystalline form having an X-ray powder diffraction pattern containing eight peaks selected from (± 0.2) 3.9, 6.1, 11.8, 14.3, 16.7, 18.3, 18.7 and 28.9 degrees 2-theta.
6. A pharmaceutical composition comprising a compound according to any of claims 1 to 5, in combination with one or more pharmaceutically acceptable diluents or carriers.
7. A pharmaceutical composition according to claim 6 which is a dry powder formulation containing the compound of formula (I) in finely divided form.
8. A pharmaceutical composition according to claim 6 which is a dry powder pharmaceutical formulation for inhalation comprising:
- (i) the compound of formula (I) in particulate form as active ingredient;
 - (ii) particulate lactose as carrier; and
 - (iii) a particulate metal salt of stearic acid.
9. A compound of formula (I) according to any of claims 1 to 5 for use as a

medicament.

10. A compound of formula (I) according to any of claims 1 to 5 or a pharmaceutical composition according to any one of claims 6 to 8 for use in the treatment or prevention of exacerbations in patients with chronic respiratory disease, such as COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis.
11. A compound of formula (I) according to any of claims 1 to 5 or a pharmaceutical composition according to any one of claims 6 to 8 for use in the treatment or prevention of a condition selected from: COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.
12. A compound of formula (I) according to any of claims 1 to 5 or a pharmaceutical composition according to any one of claims 6 to 8 for use as in the treatment or prevention of respiratory viral infections in patients with chronic conditions such as congestive heart failure, diabetes, cancer, or in immunosuppressed patients, for example post-organ transplant.
13. A compound of formula (I) according to any of claims 1 to 5 or a pharmaceutical composition according to any one of claims 6 to 8 in combination with anti-viral therapy such as zanamivir or oseltamivir (for example oseltamivir phosphate), for use in the treatment or prevention of respiratory viral infections in patients with chronic conditions such as congestive heart failure, diabetes, cancer, or in immunosuppressed patients, for example post-organ transplant.
14. A combination product comprising:
 - (A) a compound of formula (I) according to any of claims 1 to 5; and
 - (B) another therapeutic agent;wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable diluent or carrier;
wherein said combination product may be either a single pharmaceutical formulation or a kit-of-parts.
15. A compound of formula (I) according to any one of claims 1 to 5 for use in the treatment of respiratory disorders in combination with one or more other active

ingredients selected from: steroids, beta agonists, xanthines, anticholinergics, anti-viral agents, muscarinic antagonists and leukotriene antagonists.